⌘K
t
Kanabo Group plc announced a directorate change on 31 March 2023. Dan Poulter stepped down from his position as Non-Executive Director of the Company.
| Date | 31 Mar 2023 |
| Time | 14:40:01 |
| Category | Board changes |
| ID | 9997U |
31 March 2023
Kanabo Group plc
("Kanabo", the "Group" or the "Company")
Directorate Change
Kanabo Group plc (LSE: KNB), a leading patient-focused healthtech ecosystem and provider of personalised medicinal treatments, announces that Dan Poulter has stepped down as Non-Executive Director ("NED") to focus on existing commitments outside of the business.
Kanabo is at very advanced stages of appointing a new UK-based NED to join the Board of Directors, and a further announcement about this will be made imminently.
David Tsur, Chairman of Kanabo, commented:
"I would like to thank Dan for his contribution to the Company. He has been a pleasure to work with and we wish him every success in the future."
Enquiries:
|
Kanabo Group plc Avihu Tamir, Chief Executive Officer Assaf Vardimon, Chief Financial Officer
|
via Vigo Consulting +44 (0)20 7390 0230 |
|
Peterhouse Capital Ltd (Financial Adviser and Broker) Eran Zucker/ Lucy Williams / Charles Goodfellow
|
+44 (0)20 7469 0930 |
|
Vigo Consulting (Financial Public Relations/Investor Relations) Jeremy Garcia / Fiona Hetherington / Verity Snow kanabo@vigoconsulting.com |
+44 (0)20 7390 0230
|
About Kanabo Group Plc
Founded in 2017, Kanabo Group Plc (LSE:KNB) is a patient-first HealthTech ecosystem, focused on delivering high quality and innovative medical treatments, via its leading-edge technology platform and disruptive product offering.
The Company is a world leader in the research, development and commercialization of regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Patient care is delivered via the company's NHS-approved online telehealth platform offering video consultations, online prescriptions and access to primary care services. In January 2023, the Company successfully combined its technological and product expertise to launch the Beta phase of its medical cannabis business, initially for chronic pain management, under the new Treat-It brand.
Kanabo Group is committed to evolving more accessible healthcare experiences for every patient.
Visit www.kanabogroup.com for more info.